Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine in individuals aged 16–26 years in Chongqing, China

References

• De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–8. doi:10.1016/S1470-2045(12)70137-7.
   PubMed Web of Science ®Google Scholar
• Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30:F12–23. doi:10.1016/j.vaccine.2012.07.055.
   PubMed Web of Science ®Google Scholar
• Buchanan TR, Graybill WS, Pierce JY. Morbidity and mortality of vulvar and vaginal cancers: impact of 2-, 4-, and 9-valent HPV vaccines. Hum Vaccines Immunother. 2016;12:1352–6. doi:10.1080/21645515.2016.1147634.
   PubMed Web of Science ®Google Scholar
• Asiaf A, Ahmad ST, Mohammad SO, Zargar MA. Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection. Eur J Cancer Prev. 2014;23:206–24. doi:10.1097/CEJ.0b013e328364f273.
   PubMed Web of Science ®Google Scholar
• De Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70. doi:10.1002/ijc.30716.
   PubMed Web of Science ®Google Scholar
• Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, De Sanjosé S. ICO/IARC information centre on HPV and cancer (HPV information centre). Human papillomavirus and related diseases in the World. Summary Report 22 October 2021.
   Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Shi JF, Canfell K, Lew JB, Qiao YL. The burden of cervical cancer in China: synthesis of the evidence. Int J Cancer. 2012;130(3):641–52. doi:10.1002/ijc.26042.
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Pearse A, Montoya GD, Robertson M, Shearman CA, Castle PE. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer. 2013;132(1):198–207. doi:10.1002/ijc.27608.
   PubMed Web of Science ®Google Scholar
• Dareng EO, Ma B, Famooto AO, Akarolo-Anthony SN, Offiong RA, Olaniyan O, Dakum PS, Wheeler CM, Fadrosh D, Yang H, et al. Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women. Epidemiol Infect. 2016;144(1):123–37. doi:10.1017/S0950268815000965.
   PubMed Web of Science ®Google Scholar
• Teka B, Gizaw M, Ruddies F, Addissie A, Chanyalew Z, Skof AS, Thies S, Mihret A, Kantelhardt EJ, Kaufmann AM, et al. Population-based human papillomavirus infection and genotype distribution among women in rural areas of south Central Ethiopia. Int J Cancer. 2021;148(3):723–30. doi:10.1002/ijc.33278.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Qian F, Zou W, Wu X, Liu C, Shen G, Lai S, Yang S. Prevalence and genotype distribution of human papillomavirus infection in Huzhou city, eastern China, 2018–2019. Trans Royal Soc Trop Med Hyg. 2021;115(1):30–7. doi:10.1093/trstmh/traa077.
   PubMed Web of Science ®Google Scholar
• Chen X, Xu H, Xu W, Zeng W, Liu J, Wu Q, Zhao X, Jiang T. Prevalence and genotype distribution of human papillomavirus in 961,029 screening tests in Southeastern China (Zhejiang Province) between 2011 and 2015. Sci Rep. 2017;7(1):14813. doi:10.1038/s41598-017-13299-y.
   PubMedGoogle Scholar
• Luo Q, Lang L, Han N, Liang L, Shen L, Zhang H. Prevalence and genotype distribution of high-risk human papillomavirus infection among women with cervical cytological abnormalities in Chongqing, China, 2014–2020. Diagn Cytopathol. 2021;49(12):1237–43. doi:10.1002/dc.24891.
   PubMed Web of Science ®Google Scholar
• De Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin H-R, et al. Human papillomavirus genotype attribution in invasive cervi-cal cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–56. doi:10.1016/S1470-2045(10)70230-8.
   PubMed Web of Science ®Google Scholar
• Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch FX, de Sanjosé S. Potential impact of a nine-valent vaccine in human papillomavirus related cervical dis-ease. Infect Agents Cancer. 2012;7:38. doi:10.1186/1750-9378-7-38.
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, Joura EA, Maldonado P, Laco J, Bravo IG, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013;49:3450–61. doi:10.1016/j.ejca.2013.06.033.
   PubMed Web of Science ®Google Scholar
• Alemany L, Saunier M, Alvarado-Cabrero I, Quiros B, Salmeron J, Shin HR, Pirog EC, Guimerà N, Hernandez-Suarez G, Felix A, et al. Human papillomavirus DNA prevalence and type distribution in anal carcino-mas worldwide. Int J Cancer. 2014;136:98–107. doi:10.1002/ijc.28963.
   PubMed Web of Science ®Google Scholar
• Alemany L, Saunier M, Tinoco L, Quiros B, Alvarado-Cabrero I, Alejo M, Joura EA, Maldonado P, Klaustermeier J, Salmerón J, et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: aworldwide study in 597 samples. Eur J Cancer. 2014;50(16):2846–54. doi:10.1016/j.ejca.2014.07.018.
   PubMed Web of Science ®Google Scholar
• Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24:S35–41. doi:10.1016/j.vaccine.2006.06.015.
   Web of Science ®Google Scholar
• Joura E, Giuliano A, Iversen OE, Bouchard C. 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–23. doi:10.1056/NEJMoa1405044.
   PubMed Web of Science ®Google Scholar
• Pan XF, Li R, Pan A, Larson H. Human papillomavirus vaccine approval in China: a major step forward but challenges ahead. Lancet Infect Dis. 2016;16(12):1322–3. doi:10.1016/S1473-3099(16)30450-9.
   PubMed Web of Science ®Google Scholar
• Chen W, Zhao Y, Xie X, Liu J, Li J, Zhao C, Wang S, Liao X, Shou Q, Zheng M, et al. Safety of a quadrivalent human papillomavirus vaccine in a phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up. Vaccine. 2019;37(6):889–97. doi:10.1016/j.vaccine.2018.12.030.
   PubMed Web of Science ®Google Scholar
• Baloch Z, Yasmeen N, Li Y, Zhang W, Lu H, Wu X, Xia X, Yang S. Knowledge and awareness of cervical cancer, human papillomavirus (HPV), and HPV vaccine among HPV-infected Chinese women. Med Sci Monit. 2017;23:4269–77. doi:10.12659/MSM.903370.
   PubMed Web of Science ®Google Scholar
• Chen R, Wong E. The feasibility of universal HPV vaccination program in Shenzhen of China: a health policy analysis. BMC Pub Health. 2019;19:781. doi:10.1186/s12889-019-7120-7.
   PubMed Web of Science ®Google Scholar
• Hanley SJ, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. Lancet. 2015;385(9987):2571. doi:10.1016/S0140-6736(15)61152-7.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Ueda Y, Egawa-Takata T, Yagi A, Yoshino K, Kimura T. Outcomes for girls without HPV vaccination in Japan. Lancet Oncol. 2016;17(7):868–9. doi:10.1016/S1470-2045(16)00147-9.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Global advisory committee on vaccine safety, 2–3 December 2015. Wkly Epidemiol Rec. 2016;91:21–32.
   PubMedGoogle Scholar
• International Papillomavirus Society. IPVS policy statement on safety of HPV vaccines. Papillomavirus Res. 2016;2:9–10. doi:10.1016/j.pvr.2015.11.001.
   PubMedGoogle Scholar
• World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec. 2017;92:241–68.
   PubMedGoogle Scholar
• Global Advisory Committee on Vaccine Safety, World Health Organization (WHO). Statement on safety of HPV vaccines.
   Google Scholar
• World Health Organization (WHO). Guide to introducing HPV vaccine into national immunization programmes.
   Google Scholar
• Hanley SJB, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. Lancet. 2015;385(9987):2571. doi:10.1016/S0140-6736(15)61152-7.
   PubMed Web of Science ®Google Scholar
• Tsuda K, Yamamoto K, Leppold C, Tanimoto T, Kusumi E, Komatsu T, Kami M. Trends of media coverage on human papillomavirus vaccination in Japanese newspapers. Clin Infect Dis. 2016;63:1634–8. doi:10.1093/cid/ciw647.
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New Engl J Med. 2015;372:711–23. doi:10.1056/NEJMoa1405044.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Brodszki N, Van Damme P, Diez-Domingo J, Icardi G, Petersen LK, Tran C, Thomas S, Luxembourg A, Baudin M. A randomized, Double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus Gardasil® in 9–15-year-old girls. Pediat Infect Dis J. 2015;34(9):992–8. doi:10.1097/INF.0000000000000773.
   PubMed Web of Science ®Google Scholar
• Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen O-E, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, et al. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials. Pediatrics. 2016;138(2):e20154387. doi:10.1542/peds.2015-4387.
   PubMed Web of Science ®Google Scholar
• Martínez-Lavín M, Amezcua-Guerra L. Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series. Clin Rheumatol. 2017;36(10):2169–78. doi:10.1007/s10067-017-3768-5.
   PubMed Web of Science ®Google Scholar
• Yang DY. Update on the new 9-valent vaccine for human papillomavirus prevention. Can Fam Phys. 2016;62:399–402.
   PubMed Web of Science ®Google Scholar